Filing Details
- Accession Number:
- 0001209191-20-064582
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-18 21:08:39
- Reporting Period:
- 2020-12-17
- Accepted Time:
- 2020-12-18 21:08:39
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1623526 | Stoke Therapeutics Inc. | STOK | Pharmaceutical Preparations (2834) | 471144582 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1780085 | M. Huw Nash | C/O Stoke Therapeutics, Inc. 45 Wiggins Avenue Bedford MA 01730 | Coo & Cbo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-12-17 | 41,985 | $0.60 | 41,985 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-12-17 | 41,985 | $60.00 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-12-18 | 8,015 | $0.60 | 8,015 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-12-18 | 8,015 | $60.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2020-12-17 | 41,985 | $0.00 | 41,985 | $0.60 |
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2020-12-18 | 8,015 | $0.00 | 8,015 | $0.60 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
180,386 | 2028-04-02 | No | 4 | M | Direct | |
172,371 | 2028-04-02 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The option vested as to 1/48th of the total shares on February 28, 2018, and then 1/48th of the total shares vest at the end of each month thereafter, subject to the reporting person's continued service to the issuer through each vesting date.